COG Phase III Atypical Teratoid/Rhabdoid Tumors of the CNS

Protocol Title
ACNS0333 Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation

COG Principal Investigator Study Coordinator
Children’s Oncology Group Joel Kaplan, DO, MPH Wendy Bissette, RN, BS
joel.kaplan@carolinashealthcare.org

Status
Active

Key Inclusion Criteria*
- Patients from birth to < 22 years of age at time of definitive surgery who have CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) or whose tumors have a mutation of the INI1 gene even if the tumor does not have the usual histologic characteristics of AT/RT
- Corticosteroids are allowable for all patients
- Patients with MRI evidence of spinal disease are eligible
- Adequate renal, liver, cardiac, pulmonary, and bone marrow function
- Life expectancy > 8 weeks

Key Exclusion Criteria*
- Patients with extraneural metastasis (M4) or renal rhabdoid tumors
- Pregnant or breastfeeding females

Therapies
Chemotherapy
- Vincristine
- Methotrexate
- Etoposide
- Cyclophosphamide
- Cisplatin
- Carboplatin
- Thiotepa
- Leucovorin
- Mesna

Hematopoietic Stem Cell Rescue
Radiation
Surgery

Referrals
Please contact for referrals and/or study information:
Wendy Bissette, RN
Ph 704-355-9081
wendy.bissette@carolinashealthcare.org

* Additional criteria apply. rev. 02/11